Effects of vernakalant and flecainide on atrial contractility in patients with atrial fibrillation De effecten van vernakalant en flecaïnide op de atriale contractiliteit bij patiënten met atriumfibrilleren

Trial Profile

Effects of vernakalant and flecainide on atrial contractility in patients with atrial fibrillation De effecten van vernakalant en flecaïnide op de atriale contractiliteit bij patiënten met atriumfibrilleren

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Flecainide (Primary) ; Vernakalant (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jul 2012 Planned initiation date 1 Aug 2012, lead trial investigators added and planned number of patients changed from 50 to 70 as reported by ClinicalTrials.gov record.
    • 19 Jul 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health NCT01646281).
    • 19 Jul 2012 Planned End Date changed from 25 Jun 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top